NCT00348595View on ClinicalTrials.gov

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

77

Participants

Timeline

Start Date

July 20, 2006

Primary Completion Date

June 29, 2016

Study Completion Date

June 29, 2016

Conditions

Prostate Cancer

Interventions

DRUG

Revlimid

one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)

Trial Locations (1)

21230

The Harry and Jeanette Weinberg Building, Baltimore

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER